Junctional Epidermolysis Bullosa (JEB)
Gene or Region: LAMC2
Reference Variant: -
Mutant Variant: C
Affected Breeds: Belgian, Trait Brenton, Trait Comtois
Research Confidence: High - Findings reproduced multiple studies
Explanation of Results: jeb1/jeb1 = homozygous for Junctional Epidermolysis Bullosa, trait expressed jeb1/n = heterozygous for Junctional Epidermolysis Bullosa, carrier n/n = no variant detected jeb2/jeb2 = homozygous for Junctional Epidermolysis Bullosa Type 2, trait expressed jeb2/n = heterozygous for Junctional Epidermolysis Bullosa Type 2, carrier n/n = no variant detected
General Description for Junctional Epidermolysis Bullosa
Junctional epidermolysis bullosa (JEB), also known as red foot disease or hairless foal syndrome, results in the inability to produce the proteins needed to keep the skin on the body. Affected foals exhibit symptoms within days of birth, including blisters at the pressure points, detatchment of the hooves, and oral ulcers. As there is no treatment, affected foals are humanely euthanized. JEB is an autosomal recessive condition, thus a horse must inherit two copies of the allele (JEB1/JEB1) to show any signs. Horses with only one copy of the allele (JEB1/n) are known as carriers due to their ability to produce affected foals.
Gene Information
LAMC2 is a subunit of a key component of basement membranes. Mutations in other subunits of this complex have been shown to result in JEB in many human populations. This particular mutation is a single base insertion that disrupts the normal amino acid sequence, resulting in an early stop codon and truncated protein.
References
Spirito F et al., “Animal models for skin blistering conditions: absence of laminin 5 causes hereditary junctional mechanobullous disease in the Belgian horse.” (2002) J Invest Dermatol. 119: 684-91. PMID: 12230513
Milenkovic D et al., “A mutation in the LAMC2 gene causes the Herlitz junctional epidermolysis bullosa (H-JEB) in two French draft horse breeds.” (2003) Genet Sel Evol. 35: 249-56. PMID: 12633536
More Horse Health
Equine Metabolic Syndrome / Laminitis Risk
Equine Metabolic Syndrome (EMS) is a wide-spread issue in the horse population. Primarily characterized by hyperinsulinemia (excess insulin circulating in the blood in relation to glucose levels), this metabolic disorder is often present in obese horses and ponies and can be challenging to diagnose as it can be misdiagnosed as "Cushing's" (a pituitary disfunction).
Equine Recurrent Uveitis Risk and Severity
Equine Recurrent Uveitis (ERU) is the most common cause of blindness in horses, affecting about 3-15% of the horse population worldwide. Characterized by episodes of inflammation of the middle layer of the eye, Equine Recurrent Uveitis in horses leads to the development of cataracts, glaucoma and eventually complete loss of vision.
Foal Immunodeficiency Syndrome
Foal immunodeficiency syndrome (FIS) is a failure in the development of the adaptive immune system. At 3-6 weeks of age, once the maternal antibodies begin to degrade, foals exhibit signs of anemia, diarrhea, and pneumonia. As these foals fail to respond to treatment for infections, they are humanely euthanized at a young age.
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia (GT) is a blood platelet function disorder, resulting from a reduction in the platelet fibrinogen receptor protein. Clinical signs can be characterized by bleeding on the skin or from the mouth/nostril/gastrointestinal mucosas, and may include skin rashes with blood spots under the skin, nasal bleeding, gastrointestinal and gingival bleedings.